The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 104,806 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments targeting conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
YTD Price Performance: 12.56%
Average Trading Volume: 667
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.07B
Learn more about NEU stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com